Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Beginner level

Regeneron Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Accounts payable 475,500  443,100  380,100  347,800  418,100  335,600  244,000  239,600  218,200  172,361  171,906  207,611  178,183  —  —  —  —  —  —  — 
Accrued expenses and other current liabilities 1,521,800  1,303,000  1,257,000  1,143,200  1,086,800  821,100  876,700  741,100  772,100  781,924  670,709  666,216  637,162  818,760  716,761  1,062,653  880,274  718,502  763,338  746,784 
Debt —  —  1,500,000  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Finance lease liabilities, current portion —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  7,200  129,557  —  —  — 
Deferred revenue, Sanofi 341,700  409,300  380,200  398,000  395,500  427,100  424,300  334,100  246,700  246,812  308,179  231,447  177,746  187,036  184,452  112,161  115,267  105,041  104,141  99,314 
Deferred revenue, other 236,000  85,500  81,300  81,200  196,200  181,600  168,100  196,600  205,800  216,133  180,396  160,466  142,392  132,832  127,804  126,257  116,397  137,642  84,084  73,626 
Other liabilities, Sanofi 122,400  96,900  103,800  85,000  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Current liabilities 2,697,400  2,337,800  3,702,400  2,055,200  2,096,600  1,765,400  1,713,100  1,511,400  1,442,800  1,417,230  1,331,190  1,265,740  1,135,483  1,138,628  1,029,017  1,308,271  1,241,495  961,185  951,563  919,724 
Long-term debt 1,978,500  1,978,300  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Finance lease liabilities, excluding current portion 717,200  716,500  715,900  715,200  713,900  712,700  711,300  709,900  708,500  707,203  705,903  704,645  703,453  702,317  701,173  700,407  351,569  382,228  361,523  362,230 
Deferred revenue, Sanofi 16,700  37,900  37,800  16,200  509,700  551,900  544,200  633,700  279,300  421,196  339,040  406,778  379,936  408,786  443,904  520,191  503,474  529,791  549,342  565,773 
Deferred revenue, other 41,100  67,000  67,000  65,900  109,300  131,900  181,200  178,800  184,900  197,651  199,401  257,967  249,263  274,666  295,621  316,227  327,298  327,868  146,449  170,658 
Other liabilities, Sanofi 189,300  367,000  390,300  450,500  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Other noncurrent liabilities 497,800  454,000  457,900  321,500  286,000  273,000  267,900  376,300  361,700  194,033  190,020  169,922  152,073  125,225  115,920  106,248  100,385  135,700  119,523  120,993 
Noncurrent liabilities 3,440,600  3,620,700  1,668,900  1,569,300  1,618,900  1,669,500  1,704,600  1,898,700  1,534,400  1,520,083  1,434,364  1,539,312  1,484,725  1,510,994  1,556,618  1,643,073  1,282,726  1,375,587  1,176,837  1,219,654 
Total liabilities 6,138,000  5,958,500  5,371,300  3,624,500  3,715,500  3,434,900  3,417,700  3,410,100  2,977,200  2,937,313  2,765,554  2,805,052  2,620,208  2,649,622  2,585,635  2,951,344  2,524,221  2,336,772  2,128,400  2,139,378 
Preferred Stock, $.01 par value; none issued and outstanding —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Class A Stock, convertible, $.001 par value —  —  —  —  —  —  —  —  — 
Common Stock, $.001 par value 100  100  100  100  100  100  100  100  100  110  110  110  110  109  109  108  108  107  107  107 
Additional paid-in capital 6,716,200  6,592,800  6,263,000  5,211,400  4,428,600  4,388,400  4,263,600  4,160,900  3,911,600  3,841,174  3,712,599  3,611,599  3,512,833  3,570,673  3,449,622  3,190,882  3,029,993  3,314,982  3,156,942  3,049,651 
Retained earnings 10,893,000  9,743,800  8,901,700  8,004,400  7,379,800  6,587,800  5,918,200  5,725,100  5,254,300  4,433,904  3,839,179  3,287,767  2,946,733  2,773,214  2,384,897  1,997,153  1,748,222  1,495,107  1,230,303  1,018,436 
Accumulated other comprehensive income (loss) 29,300  30,800  35,500  (9,100) 21,100  16,500  15,800  2,800  (12,300) (10,519) (11,612) (15,594) 640  23,835  2,348  (5,884) (12,840) (2,899) 5,204  4,364 
Treasury Stock, at cost (6,613,300) (6,242,000) (6,142,900) (1,073,800) (739,900) (488,400) (441,800) (444,200) (396,400) (396,371) (353,852) (316,240) (316,240) (316,240) (316,240) (316,240) (316,240) (316,052) (316,052) (307,478)
Stockholders’ equity 11,025,300  10,125,500  9,057,400  12,133,000  11,089,700  10,504,400  9,755,900  9,444,700  8,757,300  7,868,300  7,186,426  6,567,644  6,144,078  6,051,593  5,520,738  4,866,021  4,449,245  4,491,247  4,076,506  3,765,082 
Total liabilities and stockholders’ equity 17,163,300  16,084,000  14,428,700  15,757,500  14,805,200  13,939,300  13,173,600  12,854,800  11,734,500  10,805,613  9,951,980  9,372,696  8,764,286  8,701,215  8,106,373  7,817,365  6,973,466  6,828,019  6,204,906  5,904,460 

Based on: 10-K (filing date: 2021-02-08), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Regeneron Pharmaceuticals Inc.’s current liabilities decreased from Q2 2020 to Q3 2020 but then slightly increased from Q3 2020 to Q4 2020.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Regeneron Pharmaceuticals Inc.’s noncurrent liabilities increased from Q2 2020 to Q3 2020 but then slightly decreased from Q3 2020 to Q4 2020.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Regeneron Pharmaceuticals Inc.’s total liabilities increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Regeneron Pharmaceuticals Inc.’s stockholders’ equity increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.